The Buerger’s Disease and the Cryoglobulinemia, the Same Old Love?
1. Abstract The type I cryoglobulinemia vasculitis is a life-threatening disorder because of the severity of cutaneous and renal involvement and the underlying hemopathy and even a limited quantity of paraproteins can cause severe symptoms and the Type I cryoglobulinemia accounts for 10%–15% of patients with cryoglobulinemia
A Rare Case of Successful Multiple Prolonged Runs of Extracorporeal Life Support for Severe Covid-19-Related Acute Respiratory Distress Syndrome
Editorial Extracorporeal life support (ECLS) is used worldwide as rescue therapy to manage severe COVID-19-related acute respiratory distress syndrome (ARDS). In patients supported with venovenous extracorporeal membrane oxygenation (VV ECMO) for COVID- 19-related ARDS, the overall mortality rate is approximately 39%, and the mean ECMO duration (approximately 15 days) seems to be longer than that […]
Streptococcus mutans in the oral cavity as a risk factor for threatened miscarriage.
Dear Editor, we have found that the presence of Streptococcus mutans in the oral cavity of a pregnant woman may be a risk factor for miscar riage. We observed that Streptococcus mutans is significantly more widespread in the oral cavity of women with threatened abortion than in those undergoing a healthy pregnancy.
Oral Terbinafine Plus Systemic Glucantime Vs. Systemic Glu- cantime Alone in The Treatment of Cutaneous Leishmaniasis
Cutaneous Leishmaniasis(CL) as an endemic disease is a major health problem in Isfahan, a large province in Iran. To date, pentavalentantimonials are the first line treatment in all types ofleishmaniasis [1]. However, their cost, side effects and the problem with injection route, necessitate furtherstudy.
Living longer and Living better
It was with great enthusiasm that we have seen the results published by Francis et al. concerning the adjuvant hormone therapy. In the SOFT study, the 8 year disease-free survival rate was 78.9% in patients who did only tamoxifen, 83.2% with tamoxifen and ovarian suppression, and 85.9% with exemestane and ovarian suppression